Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

Journal of Clinical Oncology

Volumn 29, Issue 21, 2011, Pages 2889-2896

  Thol, Felicitas ^a   Damm, Frederik ^a   Lüdeking, Andrea ^a   Winschel, Claudia ^a   Wagner, Katharina ^a   Morgan, Michael ^a   Yun, Haiyang ^a   Göhring, Gudrun ^a   Schlegelberger, Brigitte ^a   Hoelzer, Dieter ^c   Lübbert, Michael ^d   Kanz, Lothar ^e   Fiedler, Walter ^f   Kirchner, Hartmut ^b   Heil, Gerhard ^a,g   Krauter, Jürgen ^a   Ganser, Arnold ^a   Heuser, Michael ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Krankenhaus Siloah   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g Clinic of Cardiology and Angiology Klinikum Lüdenscheid   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; MEMBRANE PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 1; MIXED LINEAGE LEUKEMIA PROTEIN 5; NUCLEOPHOSMIN; PROTEIN EVI1; PROTEIN IDH1; PROTEIN IDH2; PROTEIN MN1; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; DNA METHYLATION; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGE FACTORS; DISEASE-FREE SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79960735923     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.4894     Document Type: Article

References (32)

1. Fröhling S, Scholl C, Gilliland DG, et al: Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 23:6285-6295, 2005 (Pubitemid 46218838)
2. Marcucci G, Haferlach T, Dohner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 29:475-486, 2011
3. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
4. Koschmieder S, Halmos B, Levantini E, et al: Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 27:619-628, 2009
5. Dufour A, Schneider F, Metzeler KH, et al: Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 28:570-577, 2010
6. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
7. Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72, 2008
8. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010
9. Yamashita Y, Yuan J, Suetake I, et al: Array-based genomic resequencing of human leukemia. Oncogene 29:3723-3731, 2010
10. Figueroa ME, Lugthart S, Li Y, et al: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13-27, 2010
11. Heil G, Krauter J, Raghavachar A, et al: Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: Results of a prospective multicenter trial. Ann Hematol 83:336-344, 2004 (Pubitemid 38684445)
12. Thol F, Weissinger EM, Krauter J, et al: IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668-1674, 2010
13. Mitelman F: ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1995
14. Damm F, Oberacker T, Thol F, et al: Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol 29:682-689, 2011
15. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004 (Pubitemid 41095065)
16. Döhner K, Tobis K, Ulrich R, et al: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20:3254-3261, 2002 (Pubitemid 34831523)
17. Damm F, Heuser M, Morgan M, et al: Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28:578-585, 2010
18. Wagner K, Damm F, Gohring G, et al: Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356-2364, 2010
19. Thol F, Damm F, Wagner K, et al: Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614-616, 2010
20. Baldus CD, Martus P, Burmeister T, et al: Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739-3745, 2007 (Pubitemid 47376607)
21. Marcucci G, Maharry K, Whitman SP, et al: High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular riskbased classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 25:3337-3343, 2007 (Pubitemid 47325620)
22. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al: High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 101:837-845, 2003
23. Heuser M, Beutel G, Krauter J, et al: High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898-3905, 2006 (Pubitemid 44864574)
24. Heuser M, Argiropoulos B, Kuchenbauer F, et al: MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110:1639-1647, 2007 (Pubitemid 47443982)
25. Heuser M, Wingen LU, Steinemann D, et al: Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 90:1484-1492, 2005 (Pubitemid 41658761)
26. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550, 2005 (Pubitemid 41528093)
27. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
28. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
29. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial - The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998 (Pubitemid 28452973)
30. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
31. Schlenk RF, Dohner K, Kneba M, et al: Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 94:54-60, 2009
32. Damm F, Heuser M, Morgan M, et al: Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561-4568, 2011